Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
27 Mar 2024
27 Mar 2024
Historique:
received:
12
09
2023
accepted:
26
02
2024
revised:
20
02
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
aheadofprint
Résumé
There are no large head-to-head phase 3 clinical trials comparing overall survival (OS) for abiraterone and enzalutamide. This study used Medicare claims data to compare OS in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated abiraterone or enzalutamide. This retrospective analysis of the Medicare database (2009-2020) included adult men with ≥1 claim for prostate cancer, metastatic diagnosis, and no prior chemotherapy or novel hormone therapy who initiated first-line (1L) abiraterone or enzalutamide in the index period (September 10, 2014 to May 31, 2017). Cox proportional-hazards models with inverse probability treatment-weighting (IPTW) were used to compare OS between abiraterone- and enzalutamide-treated patients, adjusting for baseline characteristics. Subgroup analyses by baseline characteristics were also conducted. Overall, 5506 patients who received 1L abiraterone (n = 2911) or enzalutamide (n = 2595) were included. Median follow-up was comparable in both cohorts (abiraterone, 19.1 months; enzalutamide, 20.3 months). IPTW-adjusted median OS (95% CI) was 20.6 months (19.7‒21.4) for abiraterone and 22.5 months (21.2‒23.8) for enzalutamide, with an IPTW-adjusted hazard ratio (95% CI) of 1.10 (1.04-1.16). Median OS was significantly shorter for abiraterone versus enzalutamide in patients ≥75 years old; White patients; patients with baseline diabetes, cardiovascular disease, both diabetes and cardiovascular disease, and renal disease; and across all socioeconomic strata. In the Medicare chemotherapy-naïve mCRPC population, 1L abiraterone was associated with worse OS versus enzalutamide in the overall population and among subgroups with older age and comorbidities, supporting findings from previous real-world studies and demonstrating a disparity in outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
There are no large head-to-head phase 3 clinical trials comparing overall survival (OS) for abiraterone and enzalutamide. This study used Medicare claims data to compare OS in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated abiraterone or enzalutamide.
METHODS
METHODS
This retrospective analysis of the Medicare database (2009-2020) included adult men with ≥1 claim for prostate cancer, metastatic diagnosis, and no prior chemotherapy or novel hormone therapy who initiated first-line (1L) abiraterone or enzalutamide in the index period (September 10, 2014 to May 31, 2017). Cox proportional-hazards models with inverse probability treatment-weighting (IPTW) were used to compare OS between abiraterone- and enzalutamide-treated patients, adjusting for baseline characteristics. Subgroup analyses by baseline characteristics were also conducted.
RESULTS
RESULTS
Overall, 5506 patients who received 1L abiraterone (n = 2911) or enzalutamide (n = 2595) were included. Median follow-up was comparable in both cohorts (abiraterone, 19.1 months; enzalutamide, 20.3 months). IPTW-adjusted median OS (95% CI) was 20.6 months (19.7‒21.4) for abiraterone and 22.5 months (21.2‒23.8) for enzalutamide, with an IPTW-adjusted hazard ratio (95% CI) of 1.10 (1.04-1.16). Median OS was significantly shorter for abiraterone versus enzalutamide in patients ≥75 years old; White patients; patients with baseline diabetes, cardiovascular disease, both diabetes and cardiovascular disease, and renal disease; and across all socioeconomic strata.
CONCLUSIONS
CONCLUSIONS
In the Medicare chemotherapy-naïve mCRPC population, 1L abiraterone was associated with worse OS versus enzalutamide in the overall population and among subgroups with older age and comorbidities, supporting findings from previous real-world studies and demonstrating a disparity in outcomes.
Identifiants
pubmed: 38538879
doi: 10.1038/s41391-024-00816-0
pii: 10.1038/s41391-024-00816-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020;78:347–57.
doi: 10.1016/j.eururo.2020.04.061
pubmed: 32527692
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.
doi: 10.1016/S1470-2045(14)71205-7
pubmed: 25601341
Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART II. J Urol. 2021;205:22–9.
doi: 10.1097/JU.0000000000001376
pubmed: 32960678
McCool R, Fleetwood K, Glanville J, Arber M, Goodall H, Naidoo S. Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer. Value Health. 2018;21:1259–68.
doi: 10.1016/j.jval.2018.03.012
pubmed: 30314628
Fang M, Nakazawa M, Antonarakis ES, Li C. Efficacy of abiraterone and enzalutamide in pre-and postdocetaxel castration-resistant prostate cancer: a trial-level meta-analysis. Prostate Cancer. 2017;2017:8560827.
doi: 10.1155/2017/8560827
pubmed: 29359049
pmcid: 5735648
Chopra A, Georgieva M, Lopes G, Yeo CM, Haaland B. Abiraterone or enzalutamide in advanced castration‐resistant prostate cancer: an indirect comparison. Prostate. 2017;77:639–46.
doi: 10.1002/pros.23309
pubmed: 28101887
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, et al. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021;24:1032–40.
doi: 10.1038/s41391-021-00318-3
pubmed: 33612825
pmcid: 8616757
Schoen MW, Carson KR, Eisen SA, Bennett CL, Luo S, Reimers MA, et al. Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis. 2023;26:743–50.
doi: 10.1038/s41391-022-00588-5
pubmed: 36104504
Marar M, Long Q, Mamtani R, Narayan V, Vapiwala N, Parikh RB. Outcomes among African American and Non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line Abiraterone. JAMA Netw Open. 2022;5:e2142093.
doi: 10.1001/jamanetworkopen.2021.42093
pubmed: 34985518
pmcid: 8733836
Scailteux L-M, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, et al. Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014–2018 French population study (the SPEAR Cohort). Am J Epidemiol. 2021;190:413–22.
doi: 10.1093/aje/kwaa190
pubmed: 32944756
Lin Y-T, Huang Y-C, Liu C-K, Lee T-S, Chen M, Chien Y-N. Treatment-emergent co-morbidities and survival in patients with metastatic castration-resistant prostate cancer receiving abiraterone or enzalutamide. Front Pharm. 2021;12:669236.
doi: 10.3389/fphar.2021.669236
Li P-Y, Lu Y-H, Chen C-Y. Comparative effectiveness of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan. Front Oncol. 2022;12:822375.
doi: 10.3389/fonc.2022.822375
pubmed: 35330713
pmcid: 8940330
Demirci A, Bilir C, Gülbağcı B, Hacıbekiroğlu İ, Bayoğlu İV, Bilgetekin İ, et al. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer. Sci Rep. 2021;11:14131.
doi: 10.1038/s41598-021-93659-x
pubmed: 34239026
pmcid: 8266820
Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, et al. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Int J Cancer. 2023;152:1191–201.
doi: 10.1002/ijc.34348
pubmed: 36346116
Chowdhury S, Bjartell A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the Prostate Cancer Registry. Target Oncol. 2020;15:301–15.
doi: 10.1007/s11523-020-00720-2
pubmed: 32500294
pmcid: 7283204
Anton A, Pillai S, Semira MC, Wong S, Shapiro J, Weickhardt A, et al. Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. BJUI Compass. 2022;3:205–13.
doi: 10.1002/bco2.129
pubmed: 35492221
Al-Ali BM, Eredics K, Madersbacher S, Schauer I. Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer. Wien Klin Wochenschr. 2018;130:659–64.
doi: 10.1007/s00508-018-1394-0
pubmed: 30324300
Soleimani M, Zou K, Sunderland K, Struss W, Eigl BJ, Nappi L, et al. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: a retrospective propensity score–weighted comparative cohort study. Eur J Cancer. 2021;152:215–22.
doi: 10.1016/j.ejca.2021.05.003
pubmed: 34130153
Baillie K, Mueller T, Pan J, Laskey J, Bennie M, Crearie C, et al. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland. Pharmacoepidemiol Drug Saf. 2020;29:653–63.
doi: 10.1002/pds.4998
pubmed: 32316077
pmcid: 8246935
Das P, Taylor S, Price J, Jones M, Martin-Fernandez C, Ali A, et al. Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: a retrospective study of real-world data (ACES). BJUI Compass. 2020;1:21–31.
doi: 10.1002/bco2.11
pubmed: 35474912
pmcid: 8988641
Alkan A, Güç ZG, Gürbüz M, Özgün G, Değirmencioğlu S, Doğan M, et al. Enzalutamide versus abiraterone acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients. J Mens Health 2021;17:128–34.
National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. 2023. https://seer.cancer.gov/statfacts/html/prost.html .
Clark R, Vesprini D, Narod SA. The effect of age on prostate cancer survival. Cancers (Basel). 2022;14:4149.
doi: 10.3390/cancers14174149
pubmed: 36077685
Centers for Medicare & Medicaid Services. Medicare and You Handbook. Baltimore, MD: U.S. Department of Health & Human Services; 2023.
Fizazi K, Tran N, Fein LE, Matsubara N, Rodríguez Antolín A, Alekseev BY, et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Abstracts of the 2017 ASCO Annual Meeting II. J Clin Oncol. 2017;35:LBA3–LBA3.
doi: 10.1200/JCO.2017.35.18_suppl.LBA3
Banna GL, Urzia V, Benanti C, Pitrè A, Lipari H, Di Quattro R, et al. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Support Care Cancer. 2020;28:4687–95.
doi: 10.1007/s00520-020-05311-5
pubmed: 31960124
Briones Carvajal JR, Naimi MF, Zhang L, Emmenegger U. Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC). Abstracts of the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium. J Clin Oncol. 2021;39:133.
doi: 10.1200/JCO.2021.39.6_suppl.133
Cuzick J, Sasieni P. Interpreting the results of noninferiority trials—a review. Br J Cancer. 2022;127:1755–9.
doi: 10.1038/s41416-022-01937-w
pubmed: 36104512
pmcid: 9643416
Hu J, Aprikian AG, Vanhuyse M, Dragomir A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin Genitourin Cancer. 2022;20:17–24.
doi: 10.1016/j.clgc.2021.08.009
pubmed: 34706850
Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol. 2020;77:158–66.
doi: 10.1016/j.eururo.2019.07.031
pubmed: 31420248
Shore ND, Saltzstein D, Sieber P, Mehlhaff B, Gervasi L, Phillips J, et al. Results of a real-world study of enzalutamide and abiraterone acetate with prednisone tolerability (REAAcT). Clin Genitourin Cancer. 2019;17:457–63.e456.
doi: 10.1016/j.clgc.2019.07.017
pubmed: 31473120
Riekhof F, Yan Y, Bennett CL, Sanfilippo KM, Carson KR, Chang S-H, et al. Hospitalizations among veterans treated for metastatic prostate cancer with abiraterone or enzalutamide. Clin Genitourin Cancer. 2023;S1558-7673:00173–8.
George DJ, Ramaswamy K, Huang A, Russell D, Mardekian J, Schultz NM, et al. Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2021;25:524–30.
doi: 10.1038/s41391-021-00463-9
pubmed: 34732856
pmcid: 9385484
George DJ, Halabi S, Fleming MT, Heath EI, Tutrone RF, Sutton L, et al. A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Abstracts of the 2023 American Society of Clinical Oncology Annual Meeting. J Clin Oncol. 2023;41:5015.
doi: 10.1200/JCO.2023.41.16_suppl.5015
Cheranda N, Luo S, Sanfilippo KM, Eisen SA, Schoen MW. Survival in Black and non-Black patients with metastatic prostate cancer. Abstracts of the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium. J Clin Oncol. 2023;41:101.
doi: 10.1200/JCO.2023.41.6_suppl.101
George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovský J, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18:284–94.
doi: 10.1016/j.clgc.2019.12.019
pubmed: 32057714